Combination of an EGFR blocker and a COX‐2 inhibitor for the treatment of advanced cutaneous squamous cell carcinoma
Summary Cutaneous squamous cell carcinoma (SCC) is one of the most common cancers worldwide. Epidermal growth factor receptor (EGFR) is expressed at the cell surface by more than 90% of SCCs and its activation is responsible for cell cycle progression, proliferation, survival, angiogenesis and metas...
Gespeichert in:
| Veröffentlicht in: | Journal der Deutschen Dermatologischen Gesellschaft 2008-12, Vol.6 (12), p.1066-1069 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng ; ger |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1069 |
|---|---|
| container_issue | 12 |
| container_start_page | 1066 |
| container_title | Journal der Deutschen Dermatologischen Gesellschaft |
| container_volume | 6 |
| creator | Jalili, Ahmad Pinc, Alice Pieczkowski, Friederike Karlhofer, Franz M. Stingl, Georg Wagner, Stephan N. |
| description | Summary
Cutaneous squamous cell carcinoma (SCC) is one of the most common cancers worldwide. Epidermal growth factor receptor (EGFR) is expressed at the cell surface by more than 90% of SCCs and its activation is responsible for cell cycle progression, proliferation, survival, angiogenesis and metastasis. Cyclooxygenase‐2 (COX‐2) is an enzyme up‐regulated through EGFR signaling and responsible for some of the EGFR‐dependent biological effects. An 88‐year‐old man presented with a recurrent, locoregionally meta‐static SCC of the right parietal region, which was resistant to radiotherapy. With a combination therapy of an EGFR blocker (cetuximab) and a COX‐2 inhibitor (celecoxib), the tumor regressed partially and the patient's Karnofsky index improved. We speculate that the combined use of cetuxi‐mab and COX‐2 inhibitors can be a new and effective therapy for advanced and recurrent cutaneous SCCs. |
| doi_str_mv | 10.1111/j.1610-0387.2008.06861.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69944480</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69944480</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2981-4170b4ed5c55da46707c87f67c1a944eb6eeec14c1c4191d5c3dd217445dd5373</originalsourceid><addsrcrecordid>eNqNkM1KxDAUhYMo_r-CZOVuatKmTboRZBxHQRBEwV1Ik1vM2DaatP7sfASf0ScxnRl0ayDkhJx77s2HEKYkoXGdLBJaUDIhmeBJSohISCEKmrxvoN3fh81fzcsdtBfCgpA0F4Rsox1a0kykPN1Fr1PXVrZTvXUddjVWHZ7NL25x1Tj9BD7eDVZ4evPw_fmVYts92sr2zuM67v4RcO9B9S10_bLYvKpOg8F66FUHbgg4vAyqHYWGpsFaeW0716oDtFWrJsDh-txH9xezu-nl5PpmfjU9u57otBR0wignFQOT6zw3ihWccC14XXBNVckYVAUAaMo01Sz-KfoyY1LKGcuNyTOe7aPjVe6zdy8DhF62NoyjrMaTRRljmCDRKFZG7V0IHmr57G2r_IekRI7M5UKOOOWIVo7M5ZK5fI-lR-seQ9WC-StcQ46G05XhzTbw8e9geX4-X8rsB79okTY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69944480</pqid></control><display><type>article</type><title>Combination of an EGFR blocker and a COX‐2 inhibitor for the treatment of advanced cutaneous squamous cell carcinoma</title><source>Wiley Online Library - AutoHoldings Journals</source><source>MEDLINE</source><creator>Jalili, Ahmad ; Pinc, Alice ; Pieczkowski, Friederike ; Karlhofer, Franz M. ; Stingl, Georg ; Wagner, Stephan N.</creator><creatorcontrib>Jalili, Ahmad ; Pinc, Alice ; Pieczkowski, Friederike ; Karlhofer, Franz M. ; Stingl, Georg ; Wagner, Stephan N.</creatorcontrib><description>Summary
Cutaneous squamous cell carcinoma (SCC) is one of the most common cancers worldwide. Epidermal growth factor receptor (EGFR) is expressed at the cell surface by more than 90% of SCCs and its activation is responsible for cell cycle progression, proliferation, survival, angiogenesis and metastasis. Cyclooxygenase‐2 (COX‐2) is an enzyme up‐regulated through EGFR signaling and responsible for some of the EGFR‐dependent biological effects. An 88‐year‐old man presented with a recurrent, locoregionally meta‐static SCC of the right parietal region, which was resistant to radiotherapy. With a combination therapy of an EGFR blocker (cetuximab) and a COX‐2 inhibitor (celecoxib), the tumor regressed partially and the patient's Karnofsky index improved. We speculate that the combined use of cetuxi‐mab and COX‐2 inhibitors can be a new and effective therapy for advanced and recurrent cutaneous SCCs.</description><identifier>ISSN: 1610-0379</identifier><identifier>EISSN: 1610-0387</identifier><identifier>DOI: 10.1111/j.1610-0387.2008.06861.x</identifier><identifier>PMID: 19138272</identifier><language>eng ; ger</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject><![CDATA[Aged, 80 and over ; Antibodies, Monoclonal - administration & dosage ; Antibodies, Monoclonal, Humanized ; Antineoplastic Agents - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols - administration & dosage ; Carcinoma, Squamous Cell - diagnosis ; Carcinoma, Squamous Cell - drug therapy ; Celecoxib ; Cetuximab ; Cyclooxygenase 2 Inhibitors - administration & dosage ; Cyclooxygenase Inhibitors - administration & dosage ; EGFR –COX‐2 ; Humans ; Male ; Pyrazoles - administration & dosage ; Receptor, Epidermal Growth Factor - antagonists & inhibitors ; Skin Neoplasms - diagnosis ; Skin Neoplasms - drug therapy ; squamous cell carcinoma ; Sulfonamides - administration & dosage ; Treatment Outcome]]></subject><ispartof>Journal der Deutschen Dermatologischen Gesellschaft, 2008-12, Vol.6 (12), p.1066-1069</ispartof><rights>The Authors • Journal compilation © Blackwell Verlag GmbH, Berlin</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2981-4170b4ed5c55da46707c87f67c1a944eb6eeec14c1c4191d5c3dd217445dd5373</citedby><cites>FETCH-LOGICAL-c2981-4170b4ed5c55da46707c87f67c1a944eb6eeec14c1c4191d5c3dd217445dd5373</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1610-0387.2008.06861.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1610-0387.2008.06861.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19138272$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jalili, Ahmad</creatorcontrib><creatorcontrib>Pinc, Alice</creatorcontrib><creatorcontrib>Pieczkowski, Friederike</creatorcontrib><creatorcontrib>Karlhofer, Franz M.</creatorcontrib><creatorcontrib>Stingl, Georg</creatorcontrib><creatorcontrib>Wagner, Stephan N.</creatorcontrib><title>Combination of an EGFR blocker and a COX‐2 inhibitor for the treatment of advanced cutaneous squamous cell carcinoma</title><title>Journal der Deutschen Dermatologischen Gesellschaft</title><addtitle>J Dtsch Dermatol Ges</addtitle><description>Summary
Cutaneous squamous cell carcinoma (SCC) is one of the most common cancers worldwide. Epidermal growth factor receptor (EGFR) is expressed at the cell surface by more than 90% of SCCs and its activation is responsible for cell cycle progression, proliferation, survival, angiogenesis and metastasis. Cyclooxygenase‐2 (COX‐2) is an enzyme up‐regulated through EGFR signaling and responsible for some of the EGFR‐dependent biological effects. An 88‐year‐old man presented with a recurrent, locoregionally meta‐static SCC of the right parietal region, which was resistant to radiotherapy. With a combination therapy of an EGFR blocker (cetuximab) and a COX‐2 inhibitor (celecoxib), the tumor regressed partially and the patient's Karnofsky index improved. We speculate that the combined use of cetuxi‐mab and COX‐2 inhibitors can be a new and effective therapy for advanced and recurrent cutaneous SCCs.</description><subject>Aged, 80 and over</subject><subject>Antibodies, Monoclonal - administration & dosage</subject><subject>Antibodies, Monoclonal, Humanized</subject><subject>Antineoplastic Agents - administration & dosage</subject><subject>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</subject><subject>Carcinoma, Squamous Cell - diagnosis</subject><subject>Carcinoma, Squamous Cell - drug therapy</subject><subject>Celecoxib</subject><subject>Cetuximab</subject><subject>Cyclooxygenase 2 Inhibitors - administration & dosage</subject><subject>Cyclooxygenase Inhibitors - administration & dosage</subject><subject>EGFR –COX‐2</subject><subject>Humans</subject><subject>Male</subject><subject>Pyrazoles - administration & dosage</subject><subject>Receptor, Epidermal Growth Factor - antagonists & inhibitors</subject><subject>Skin Neoplasms - diagnosis</subject><subject>Skin Neoplasms - drug therapy</subject><subject>squamous cell carcinoma</subject><subject>Sulfonamides - administration & dosage</subject><subject>Treatment Outcome</subject><issn>1610-0379</issn><issn>1610-0387</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkM1KxDAUhYMo_r-CZOVuatKmTboRZBxHQRBEwV1Ik1vM2DaatP7sfASf0ScxnRl0ayDkhJx77s2HEKYkoXGdLBJaUDIhmeBJSohISCEKmrxvoN3fh81fzcsdtBfCgpA0F4Rsox1a0kykPN1Fr1PXVrZTvXUddjVWHZ7NL25x1Tj9BD7eDVZ4evPw_fmVYts92sr2zuM67v4RcO9B9S10_bLYvKpOg8F66FUHbgg4vAyqHYWGpsFaeW0716oDtFWrJsDh-txH9xezu-nl5PpmfjU9u57otBR0wignFQOT6zw3ihWccC14XXBNVckYVAUAaMo01Sz-KfoyY1LKGcuNyTOe7aPjVe6zdy8DhF62NoyjrMaTRRljmCDRKFZG7V0IHmr57G2r_IekRI7M5UKOOOWIVo7M5ZK5fI-lR-seQ9WC-StcQ46G05XhzTbw8e9geX4-X8rsB79okTY</recordid><startdate>200812</startdate><enddate>200812</enddate><creator>Jalili, Ahmad</creator><creator>Pinc, Alice</creator><creator>Pieczkowski, Friederike</creator><creator>Karlhofer, Franz M.</creator><creator>Stingl, Georg</creator><creator>Wagner, Stephan N.</creator><general>Blackwell Publishing Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200812</creationdate><title>Combination of an EGFR blocker and a COX‐2 inhibitor for the treatment of advanced cutaneous squamous cell carcinoma</title><author>Jalili, Ahmad ; Pinc, Alice ; Pieczkowski, Friederike ; Karlhofer, Franz M. ; Stingl, Georg ; Wagner, Stephan N.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2981-4170b4ed5c55da46707c87f67c1a944eb6eeec14c1c4191d5c3dd217445dd5373</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng ; ger</language><creationdate>2008</creationdate><topic>Aged, 80 and over</topic><topic>Antibodies, Monoclonal - administration & dosage</topic><topic>Antibodies, Monoclonal, Humanized</topic><topic>Antineoplastic Agents - administration & dosage</topic><topic>Antineoplastic Combined Chemotherapy Protocols - administration & dosage</topic><topic>Carcinoma, Squamous Cell - diagnosis</topic><topic>Carcinoma, Squamous Cell - drug therapy</topic><topic>Celecoxib</topic><topic>Cetuximab</topic><topic>Cyclooxygenase 2 Inhibitors - administration & dosage</topic><topic>Cyclooxygenase Inhibitors - administration & dosage</topic><topic>EGFR –COX‐2</topic><topic>Humans</topic><topic>Male</topic><topic>Pyrazoles - administration & dosage</topic><topic>Receptor, Epidermal Growth Factor - antagonists & inhibitors</topic><topic>Skin Neoplasms - diagnosis</topic><topic>Skin Neoplasms - drug therapy</topic><topic>squamous cell carcinoma</topic><topic>Sulfonamides - administration & dosage</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jalili, Ahmad</creatorcontrib><creatorcontrib>Pinc, Alice</creatorcontrib><creatorcontrib>Pieczkowski, Friederike</creatorcontrib><creatorcontrib>Karlhofer, Franz M.</creatorcontrib><creatorcontrib>Stingl, Georg</creatorcontrib><creatorcontrib>Wagner, Stephan N.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal der Deutschen Dermatologischen Gesellschaft</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jalili, Ahmad</au><au>Pinc, Alice</au><au>Pieczkowski, Friederike</au><au>Karlhofer, Franz M.</au><au>Stingl, Georg</au><au>Wagner, Stephan N.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Combination of an EGFR blocker and a COX‐2 inhibitor for the treatment of advanced cutaneous squamous cell carcinoma</atitle><jtitle>Journal der Deutschen Dermatologischen Gesellschaft</jtitle><addtitle>J Dtsch Dermatol Ges</addtitle><date>2008-12</date><risdate>2008</risdate><volume>6</volume><issue>12</issue><spage>1066</spage><epage>1069</epage><pages>1066-1069</pages><issn>1610-0379</issn><eissn>1610-0387</eissn><abstract>Summary
Cutaneous squamous cell carcinoma (SCC) is one of the most common cancers worldwide. Epidermal growth factor receptor (EGFR) is expressed at the cell surface by more than 90% of SCCs and its activation is responsible for cell cycle progression, proliferation, survival, angiogenesis and metastasis. Cyclooxygenase‐2 (COX‐2) is an enzyme up‐regulated through EGFR signaling and responsible for some of the EGFR‐dependent biological effects. An 88‐year‐old man presented with a recurrent, locoregionally meta‐static SCC of the right parietal region, which was resistant to radiotherapy. With a combination therapy of an EGFR blocker (cetuximab) and a COX‐2 inhibitor (celecoxib), the tumor regressed partially and the patient's Karnofsky index improved. We speculate that the combined use of cetuxi‐mab and COX‐2 inhibitors can be a new and effective therapy for advanced and recurrent cutaneous SCCs.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>19138272</pmid><doi>10.1111/j.1610-0387.2008.06861.x</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1610-0379 |
| ispartof | Journal der Deutschen Dermatologischen Gesellschaft, 2008-12, Vol.6 (12), p.1066-1069 |
| issn | 1610-0379 1610-0387 |
| language | eng ; ger |
| recordid | cdi_proquest_miscellaneous_69944480 |
| source | Wiley Online Library - AutoHoldings Journals; MEDLINE |
| subjects | Aged, 80 and over Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal, Humanized Antineoplastic Agents - administration & dosage Antineoplastic Combined Chemotherapy Protocols - administration & dosage Carcinoma, Squamous Cell - diagnosis Carcinoma, Squamous Cell - drug therapy Celecoxib Cetuximab Cyclooxygenase 2 Inhibitors - administration & dosage Cyclooxygenase Inhibitors - administration & dosage EGFR –COX‐2 Humans Male Pyrazoles - administration & dosage Receptor, Epidermal Growth Factor - antagonists & inhibitors Skin Neoplasms - diagnosis Skin Neoplasms - drug therapy squamous cell carcinoma Sulfonamides - administration & dosage Treatment Outcome |
| title | Combination of an EGFR blocker and a COX‐2 inhibitor for the treatment of advanced cutaneous squamous cell carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T08%3A06%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Combination%20of%20an%20EGFR%20blocker%20and%20a%20COX%E2%80%902%20inhibitor%20for%20the%20treatment%20of%20advanced%20cutaneous%20squamous%20cell%20carcinoma&rft.jtitle=Journal%20der%20Deutschen%20Dermatologischen%20Gesellschaft&rft.au=Jalili,%20Ahmad&rft.date=2008-12&rft.volume=6&rft.issue=12&rft.spage=1066&rft.epage=1069&rft.pages=1066-1069&rft.issn=1610-0379&rft.eissn=1610-0387&rft_id=info:doi/10.1111/j.1610-0387.2008.06861.x&rft_dat=%3Cproquest_cross%3E69944480%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69944480&rft_id=info:pmid/19138272&rfr_iscdi=true |